Clinical Efficacy of Vericiquat Combined with Sacubitril Valsartan in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction and its Effect on Cardiac Function
Objective To explore the clinical efficacy of vericiguat combined with sacubitril valsartan in the treatment of patients with heart failure with reduced ejection fraction and its impact on cardiac function.Methods Retrospective analysis of clinical data of on 218 patients with heart failure with reduced ejection fraction admitted to Linyi Hospital of Traditional Chinese Medicine from April 2020 to April 2024,according to different treatment methods,they were divided into a control group(n=106 cases)and an observation group(n=112 cases).The control group was treated with sacubitril valsartan.The observation group was treated with vericiguat on the basis of the control group.The clinical efficacy,cardiac function,myocardial injury and occurrence of adverse reactions were compared between the two groups.Results Before treatment,the cardiac function and myocardial injury were compared between the two groups,and the differences between the groups were no statistically significant(P＞0.05);the total effective rate of treatment in the observation group was 93.75%,which was higher than 80.19%in the control group,and the difference was statistically significant(P<0.05);after treatment,the thickness of the left ventricular posterior wall and interventricular septum in the observation group were thinner than those in the control group.the left ventricular end-systolic diameter and left ventricular end-diastolic diameter in the observation group were shorter than those in the control group.the left ventricular ejection fraction in the observation group was higher than that in the control group,and the level of N-terminal pro-B-type natriuretic peptide in the observation group was lower than that in the control group,and the differences between the groups were statistically significant(P<0.05);comparison of the incidence of adverse reactions between the two groups,and the difference was no statistically significant(P＞0.05).Conclusion In patients with heart failure with reduced ejection fraction,the application of vericiguat combined with sacubitril valsartan has a significant therapeutic effect.It can effectively regulate the level of N-terminal pro-B-type natriuretic peptide,promote the improvement of cardiac function,and is safe for medication.
Heart failure with reduced ejection fractionVericiguatSacubitril valsartanClinical efficacyCardiac function
万方数据
